ELN Isn't doing as well as BIIB after the report on Tysabri's safety & side effects.
ELN Is trying to hold above the support at the $22 level,It did close its UG of May 21 at the $17 level
bigcharts.marketwatch.com
BIIB is trying to go over the resistance at 68. It didn't completely close its UG of May 30 at the $50 level
bigcharts.marketwatch.com
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Thursday October 11, 12:10 pm ET
CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB - News) and Elan Corporation, plc (NYSE: ELN - News) today announced new data on the global utilization and safety of TYSABRI® (natalizumab), citing that as of the end of September 2007 approximately 17,000 patients are on commercial and clinical therapy worldwide, and that the safety data to date continue to support a favorable benefit-risk profile for TYSABRI.
These data will be presented as part of the companies' symposia being held on Friday, October 12, 2007 at 6 p.m. CEST at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic.
As of the end of September 2007:
* In the US, approximately 10,500 patients are on TYSABRI commercially and over 2,100 physicians have prescribed the therapy;
* In the EU, approximately 5,500 patients are on TYSABRI therapy commercially; and
* In global clinical trials, approximately 1,000 patients are on TYSABRI therapy.
TYSABRI is available in the United States through the TOUCH(TM) Prescribing Program. All prescribers, infusion sites and patients receiving TYSABRI are required to enroll in TOUCH.
Safety information is also collected through ongoing clinical trials and registries, including TYGRIS and the pregnancy registry, making this the largest long-term patient follow-up effort undertaken for any MS therapy.
According to data available to the companies as of mid-September 2007, there have been no new reports of confirmed cases of progressive multifocal leukoencephalopathy (PML).
The safety data to date continue to support a favorable benefit-risk profile for TYSABRI. The companies plan to continue to provide similar updates at future medical meetings.
"Neurologists and patients are increasingly choosing TYSABRI given its significant impact on clinically meaningful and relevant endpoints, including relapses and disability progression.
Ultimately, we believe the full potential of TYSABRI will be realized, making it the leading MS therapy," said Michael Panzara, MD, MPH, Vice President and Chief Medical Officer, Neurology Strategic Business Unit, Biogen Idec.
"Continued patient experience and ongoing clinical research will further differentiate TYSABRI as a valuable treatment option for MS patients around the world.
TYSABRI is currently approved in more than 20 countries, and we hope to offer this therapeutic alternative to more patients in the future," said Gordon Francis, MD, Senior Vice President, Global Clinical Development, Elan.
Snip
biz.yahoo.com
Bernard |
